Review of current nonsurgical management of Peyronie's disease

International Journal of Impotence Research

Volumn 15, Issue SUPPL. 5, 2003, Pages

  Levine, L A ^a,b  

^a RUSH MEDICAL COLLEGE   (United States)

^b NONE   (United States)

Author keywords

Medical therapy; Peyronie's disease; Treatment options

Indexed keywords

4 AMINOBENZOATE POTASSIUM; ALPHA TOCOPHEROL; ALPHA2B INTERFERON; AMINE OXIDASE (FLAVIN CONTAINING); ANTIOXIDANT; ARACHIDONIC ACID; ARSENIC; CAMPHOR; CLOSTRIDIOPEPTIDASE A; COLCHICINE; COLLAGEN; CORTISONE; DEXAMETHASONE; FIBRONECTIN; HYDROCORTISONE; IODINE; LEVACECARNINE; LIDOCAINE; MERCURY; NIFEDIPINE; PLACEBO; PROPIONYLCARNITINE; SEROTONIN; STEROID; SUPEROXIDE DISMUTASE; TAMOXIFEN; TRANSFORMING GROWTH FACTOR BETA; TRIAMCINOLONE HEXACETONIDE; UNINDEXED DRUG; VERAPAMIL;

ADRENAL INSUFFICIENCY; CLINICAL PRACTICE; CLINICAL TRIAL; CONFERENCE PAPER; CONSERVATIVE TREATMENT; DIARRHEA; DISEASE COURSE; DRUG ADMINISTRATION ROUTE; DRUG COST; DRUG DELIVERY SYSTEM; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; ENERGY TRANSFER; EXTRACORPOREAL LITHOTRIPSY; FEVER; FLU LIKE SYNDROME; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HAIR LOSS; HUMAN; IONTOPHORESIS; JET INJECTOR; MEDICAL SPECIALIST; MYALGIA; NONHUMAN; OUTCOMES RESEARCH; PATIENT CARE; PEYRONIE DISEASE; PRACTICE GUIDELINE; PRIORITY JOURNAL; TECHNIQUE; TUNICA ALBUGINEA;

ANTIOXIDANTS; CALCIUM CHANNEL BLOCKERS; COLCHICINE; COLLAGENASES; DRUG THERAPY, COMBINATION; HUMANS; MALE; PENILE INDURATION; STEROIDS; VERAPAMIL;

EID: 0142246414     PISSN: 09559930     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.ijir.3901084     Document Type: Conference Paper

References (59)

1. Mazo VE. Nov metod za lschenie na bolestta na Peironi. Khirurgiia (Sofiia) 1989; 42: 30-31.
2. Bellorofonte C et al. Possibilita di impiego del litotritore piezoelottrico nel trattamento delle fibrosi cavernose gravi. Arch Ital Urol Nefrol Androl 1989; 61; 417-422.
3. Frank IN, Scott WW. The ultrasonic treatment of Peyronie's disease. J Urol 1971; 106: 83-87.
4. Scott WW, Scardino PL. A new concept in the treatment of Peyronie's disease. South Med J 1948; 41: 173.
5. Gelbard MK, Dorey F, James K. The natural history of Peyronie's disease. J Urol 1990; 144: 1376-1379.
6. Zarafonatis CJD, Horrax TM. Treatment of Peyronie's disease with Potaba. J Urol 1953; 81: 770-772.
7. Hasche-Klunder R. Zur Behandlung der Induration penis plastica mit para-aminobenzoesaurem Kalium (PABK). Urologe A 1978; 17: 224-227.
8. Carson CC. Potassium para-aminobenzoate for the treatment of Peyronie's disease: is it effective? Tech Urol 1997; 3: 135-139.
9. Weidner W et al. Randomized prospective placebo-controlled therapy of Peyronie's disease (IPP) with Potaba* (aminobenzoate potassium). J Urol 1999; 6(Suppl): 205.
10. Ralph DJ et al. The treatment of Peyronie's disease with tamoxifen. Br J Urol 1992; 70: 648-651.
11. Colletta AA et al. Anti-oestrogens induce the secretion of active transforming growth factor beta from human fetal fibroblasts. Br J Cancer 1990; 62: 405-409.
12. Wahl SM, McCartney-Francis N, Mergenhagen SE. Inflammatory and immunomodulatory roles of TGF-b. Immunol Today 1989; 10: 258-261.
13. Teloken C et al. Tamoxifen versus placebo in the treatment of Peyronie's disease. J Urol 1999; 162: 2003-2005.
14. Akkus E et al. Is colchicine effective in Peyronie's disease? A pilot study. Urology 1994; 44: 291-295.
15. Diegelmann RF, Peterkofsky B. Inhibition of collagen secretion from bone and cultured fibroblasts by microtubular disruptive drugs. Proc Natl Acad Sci USA 1972; 69: 892-896.
16. Ehrlich HP, Bornstein P. Microtubules in transcellular movement of procollagen. Nature 1972; 238: 257-260.
17. Harris Jr ED, Krane SM. Effects of colchicine on collagenase in culture of rheumatoid synovium. Arthritis Rheum 1971; 14: 669-684.
18. Kadioglu A et al. Treatment of Peyronie's disease with oral colchicine: long-term results and predictive parameters of successful outcome. Int J Impot Res 2000; 12: 169-175.
19. Biagiotti G, Cavallini G. Acetyl-l-carnitine vs tamoxifen in the oral therapy of Peyronie's disease: a preliminary report. BJU Int 2001; 88: 63-67.
20. Cavallini G, Biagiotti G, Loverech A, Vitali G. Oral propionyl-l-carniline and intraplaque verapamil in the therapy of advanced and resistant Peyronie's disease. BJU Int 2002; 89: 895-900.
21. Tearsley GH. Peyronie's disease: the new approach. J Urol 1954; 105: 523.
22. Bodner H, Howard AH, Kaplan JH. Peyronie's disease: cortisone-hyaluronidase-hydrocortisone therapy. J Urol 1954; 134: 400.
23. Winter CC, Khanna R. Peyronie's disease: results with dermo-jet injection of dexamethasone. J Urol 1975; 14: 898-900.
24. Williams G, Green NA. The non-surgical treatment of Peyronie's disease. Br J Urol 1980; 52: 392-395.
25. Gelbard MK, Walsh R, Kaufman JJ. Collagenase for Peyronie's disease experimental studies. Urol Res 1982; 10: 135-140.
26. Gelbard MK, Lindner A, Kaufman JJ. The use of collagenase in the treatment of Peyronie's disease. J Urol 1985; 134: 280-283.
27. Gelbard MK, James N, Riach P, Dovr F. Collagenase versus placebo in the treatment of Peyronie's disease: a double blinded study. J Urol 1993; 149: 56-58.
28. Kelami A. Classification of congenital and acquired penile deviation. Urol Int 1983; 38: 229.
29. Levine LA, Merrick PF, Lee RC. Intralesional verapamil injection for the treatment of Peyronie's disease. J Urol 1994; 151: 1522-1524.
30. Kelly RB. Pathways of protein secretion in eukariots. Science 1985; 230: 25.
31. Aggler J, Frisch SM, Werb Z. Changes in cell shape correlate with collagenase gene expression in rabbit synovial fibroblasts. J Cell Biol 1984; 98: 1662.
32. Lee RC, Ping JA. Calcium antagonists retard extracellular matrix production in connective tissue equivalent. J Surg Res 1990; 49: 463.
33. Lee RC, Doong H, Jellama AF. The response of burn scars to intralesional verapamil. Report of five cases. Arch Surg 1994; 129: 107-109.
34. Roth M et al. Calcium-channel blockers modulate metabolism of collagens with the extra cellular matrix. Proc Natl Acad Sci 1996; 93: 5478-5483.
35. Anderson MS, Shankey TV, Lubrano T, Lumhall JP. Inhibition of Peyronie's plaque fibroblast proliferation by biologic agents. Int J Impot Res 2000; 12(Suppl 3): 525-531.
36. (2+)-channel blockers modulate the expression of interleukin-6 and interleukin - a genes in human vascular smooth muscle cells. J Mol Cell Cardiol 1995; 27: 2295-2298.
37. Teloken C et al. Objective evaluation of non-surgical approach for Peyronie's disease. J Urol 1996; 155: 633A (abstract 1290).
38. Rehman I, Benet A, Melman A. Use of intralesional verapamil to dissolve Peyronie's disease plaque: a long-term single-blind study. Urology 1998; 51: 620-626.
39. Levine LA, Goldman K, Greenfield J. Experience with intraplaque injection of verapamil for Peyronie's disease. J Urol 2002; 168: 621-626.
40. Duncan MR, Berman B, Nseyo UO. Regulation of the proliferation and biosynthetic activities of cultured human Peyronie's disease fibroblasts by interferons-alpha, -beta and -gamma. Scand J Urol Nephrol 1991; 25: 89-94.
41. Berman B, Duncan MR. Short-term keloid treatment in vivo with human interferon-alpha-2b results in a selective and persistent normalization of keloidal fibroblast collagen, glycosaminoglycan and collagenase production in vitro. J Am Acad Dermatol 1989; 21: 694-702.
42. Duncan MR, Berman B. Persistence of a reduced-collagen-producing phenotype in cultured scleroderma fibroblasta after short-term exposure to interferons. J Clin Invest 1987; 79: 1318-1324.
43. Wegner HE, Andresen R, Knispel HH, Miller K. Treatment of Peyronie's disease with local interferon-alpha 2b. Eur Urol 1995; 28: 236-240.
44. Wegner HE, Andresen R, Knispel HH, Miller K. Local interferon-alpha 2b is not an effective treatment in early stage Peyronie's disease. Eur Urol 1997; 32: 190-193.
45. Judge IA, Wisniewski ZS. Intralesional interferon in the treatment of Peyronie's disease: a pilot study. Br J Urol 1997; 70: 40-42.
46. Ahuja S, Bivalacqua TJ, Case J, Hellstrom WJG. A pilot study demonstrating clinical benefit from intralesional interferon alpha 2B in the treatment of Peyronie's disease. J Androl 1999; 20: 444-448.
47. Martin DJ, Badwan K, Parker M, Mulhall JP. Transdermal application of verapamil gel to penile shaft fails to infiltrate tunica albuginea. J Urol 2002; 168: 2483-2485.
48. Felipetto R, Vigano L, Pagni GL, Minervini R. Laser and ultrasonic therapy in simultaneous emission for the treatment of plastic penile induration [Italian]. Minerva Urol Nefrol 1995; 47: 25-29.
49. Riedl CR et al. Iontophoresis for treatment of Peyronie's disease. J Urol 2000; 163: 95-99.
50. Montorsi F et al. Transdermal electromotive multi-drug administration for Peyronie's disease. Preliminary results. J Androl 2000; 21: 85-90.
51. Levine LA, Estrada CR, Shou W, Cole A. Tunica albuginea tissue analysis following electromotive drug administration (EMDA). J Urol 2003; 169: 1775-1778.
52. Hussain J et al. Extracorporeal shock wave therapy in the management of Peyronie's disease: initial experience. Br J Urol 2000; 86: 466-468.
53. Manikandan R, Islam W, Srinivasan V, Evans CM. Evaluation of extracorporeal shock wave therapy in Peyronie's disease. Urology 2002; 60: 795-800.
54. Lebret T et al. Extracorporeal shock wave therapy in the treatment of Peyronie's disease: experience with standard lithotripter (Siemens-Multiline). Urology 2002; 59: 657-661.
55. Hauck IW et al. Extracorporal shock wave therapy in the treatment of Peyronie's disease. Eur Urol 2000; 38: 663-670.
56. Haupt G, Chrapil M. Effect of shockwaves on the healing of partial thickness wounds in piglets. J Surg Res 1990; 49: 45-48.
57. Kelami A. Autophotography in evaluation of functional penile disorders. Urology 1983; 21: 628-629.
58. Mirone V et al. Ultrasound-guided ESWT in Peyronie's disease plaques. Arch Ital di Urol Androl 2000; 72: 384-387.
59. Mirone V, Imbimbo C, Palmieri A, Fusco F. Our experience on the association of a new physical and medical therapy in patients suffering from induratio penis plastica. Eur Urol 1999; 36: 327-330.